CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	12 Months Ended
	Apr. 30, 2017	Apr. 30, 2016
Operating revenue:
Personalized oncology solutions	$ 1,720,000	$ 1,972,000
Translational oncology solutions	13,691,000	9,210,000
Total operating revenue	15,411,000	11,182,000
Costs and operating expenses:
Cost of personalized oncology solutions	1,433,000	2,102,000
Cost of translational oncology solutions	8,270,000	6,584,000
Research and development	4,293,000	4,194,000
Sales and marketing	3,261,000	3,445,000
General and administrative	4,963,000	5,173,000
Total costs and operating expenses	22,220,000	21,498,000
Loss from operations	(6,809,000)	(10,316,000)
Other expense:
Other expense	(56,000)	(38,000)
Total other expense	(56,000)	(38,000)
Net loss before income tax expense	(6,865,000)	(10,354,000)
Provision for income tax	19,000	92,000
Net loss	$ (6,883,882)	$ (10,445,537)
Net loss per common share outstanding basic and diluted (in dollars per share)	$ (0.64)	$ (1.20)
Weighted average common shares outstanding basic and diluted (in shares)	10,684,395	8,695,199